There was unparalleled surprise in New York when a powerful alliance of UN-backed asset owners announced it will drive it’s portfolio companies to carbon neutrality by 2050. This could mean a fundamental change in capital markets.
https://european-biotechnology.com/wp-content/uploads/2024/04/jeremy_levin.jpg6751200h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-10-17 09:25:002019-10-17 09:25:00Investors make commitment to net zero emissions by 2050
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases.
https://european-biotechnology.com/wp-content/uploads/2024/04/artificial-intelligence-Gerd_Altmann-pixabay.jpg12851920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-10-17 09:05:002019-10-17 09:05:00Healx Ltd raises $56m in Series B financing
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients.
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-10-14 07:50:002019-10-14 07:50:00QIAGEN: Temporary CEO
John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.
CHMP selects drugs for EU market approval
Latest NewsEMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.
New risk factor for autism and epilepsy identified
Latest NewsA molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders.
Investors make commitment to net zero emissions by 2050
OpinionThere was unparalleled surprise in New York when a powerful alliance of UN-backed asset owners announced it will drive it’s portfolio companies to carbon neutrality by 2050. This could mean a fundamental change in capital markets.
Healx Ltd raises $56m in Series B financing
Latest NewsAI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases.
4SC expands domatinostat combo testing
Latest NewsThe Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients.
Cell transdifferentiation specialist Mogrify Ltd raises US$16m
Latest NewsBritish start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
Patient’s organoids predict response to chemotherapy
Latest NewsA new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.
QIAGEN: Temporary CEO
AppointmentsAfter the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
ADC Therapeutics enters licence option deal with Avacta Group
Latest NewsADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.
Oerth Bio: Joint venture CEO
AppointmentsJohn Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.